Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Second Generation Inactivated COVID-19 Vaccine (Delta variant)
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Second Generation Inactivated COVID-19 Vaccine (Delta variant) is a preclinical-stage vaccine candidate being developed by AIM Honesty in collaboration with the Zhejiang Provincial Center for Disease Control and Prevention. This inactivated viral vaccine utilizes inactivated SARS-CoV-2 Delta variant particles as antigens to stimulate the immune system to produce neutralizing antibodies specifically targeted against the Delta variant. Designed for the prevention of COVID-19, the vaccine entered development in May 2021 following a cooperation agreement between the developers and was subsequently listed as a candidate in AIM Honesty's pipeline.
- Other names
- Delta variant inactivated COVID-19 vaccineSecond Generation Inactivated COVID-19 Vaccine
Beyond the preview
Go deeper on Second Generation Inactivated COVID-19 Vaccine (Delta variant).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Second Generation Inactivated COVID-19 Vaccine (Delta variant).